Pharmacogenomics in the era of next generation sequencing - from byte to bedside
Pharmacogenetic research has resulted in the identification of a multitude of genetic variants that impact drug response or toxicity. These polymorphisms are mostly common and have been included as actionable information in the labels of numerous drugs. In addition to common variants, recent advances in Next Generation Sequencing (NGS) technologies have resulted in the identification of a plethora of rare and population-specific pharmacogenetic variations with unclear functional consequences that are not accessible by conventional forward genetics strategies. In this review, we discuss how comprehensive sequencing information can be translated into personalized pharmacogenomic advice in the age of NGS. Specifically, we provide an update of the functional impacts of rare pharmacogenetic variability and how this information can be leveraged to improve pharmacogenetic guidance. Furthermore, we critically discuss the current status of implementation of pharmacogenetic testing across drug development and layers of care. We identify major gaps and provide perspectives on how these can be minimized to optimize the utilization of NGS data for personalized clinical decision-support.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 53(2021), 2 vom: 01. Mai, Seite 253-278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Russell, Laura E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 05.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03602532.2021.1909613 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323758401 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323758401 | ||
| 003 | DE-627 | ||
| 005 | 20231225184852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2021.1909613 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323758401 | ||
| 035 | |a (NLM)33820459 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Russell, Laura E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenomics in the era of next generation sequencing - from byte to bedside |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 05.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Pharmacogenetic research has resulted in the identification of a multitude of genetic variants that impact drug response or toxicity. These polymorphisms are mostly common and have been included as actionable information in the labels of numerous drugs. In addition to common variants, recent advances in Next Generation Sequencing (NGS) technologies have resulted in the identification of a plethora of rare and population-specific pharmacogenetic variations with unclear functional consequences that are not accessible by conventional forward genetics strategies. In this review, we discuss how comprehensive sequencing information can be translated into personalized pharmacogenomic advice in the age of NGS. Specifically, we provide an update of the functional impacts of rare pharmacogenetic variability and how this information can be leveraged to improve pharmacogenetic guidance. Furthermore, we critically discuss the current status of implementation of pharmacogenetic testing across drug development and layers of care. We identify major gaps and provide perspectives on how these can be minimized to optimize the utilization of NGS data for personalized clinical decision-support | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Pharmacogenomics | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a clinical implementation | |
| 650 | 4 | |a drug development | |
| 650 | 4 | |a genetic variants | |
| 650 | 4 | |a pharmacogenomic trials | |
| 650 | 4 | |a precision medicine | |
| 700 | 1 | |a Zhou, Yitian |e verfasserin |4 aut | |
| 700 | 1 | |a Almousa, Ahmed A |e verfasserin |4 aut | |
| 700 | 1 | |a Sodhi, Jasleen K |e verfasserin |4 aut | |
| 700 | 1 | |a Nwabufo, Chukwunonso K |e verfasserin |4 aut | |
| 700 | 1 | |a Lauschke, Volker M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d 1973 |g 53(2021), 2 vom: 01. Mai, Seite 253-278 |w (DE-627)NLM000049530 |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:2 |g day:01 |g month:05 |g pages:253-278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03602532.2021.1909613 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 2 |b 01 |c 05 |h 253-278 | ||